Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ANIP stock price vs SBAC: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SBAC's multiple
Needs SBAC P/E.
Implied fair value · at ANIP's multiple
Needs ANIP P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ANIP FY 2025 (ended Dec 31, 2025) · SBAC FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 84% equity / 16% debt · EV / Revenue 1.84x · EV / EBITDA 7.53x
Capital structure 58% equity / 42% debt · EV / Revenue 12.31x · EV / EBITDA 17.53x
SBAC carries the larger enterprise value at $34.66B against $1.63B; ANIP trades on the lower EV / Revenue multiple (1.84x vs 12.31x); ANIP on the lower EV / EBITDA (7.53x vs 17.53x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ANI PHARMACEUTICALS, INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
SBA COMMUNICATIONS CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.57x
-3.06x
Net debt / EBITDA
Leverage against operating earnings
0.11x
7.37x
Cash and equivalents
Liquid reserves on the balance sheet
$285.59M
$271.22M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
SUPERNUS PHARMACEUTICALS, INC.
ANIP vs SUPN
PERRIGO Co plc
ANIP vs PRGO
Viatris Inc
ANIP vs VTRS
Organon & Co.
ANIP vs OGN
TEVA PHARMACEUTICAL INDUSTRIES LTD
ANIP vs TEVA
AMERICAN TOWER CORP /MA/
ANIP vs AMT
ORACLE CORP
ANIP vs ORCL
EQUINIX INC
ANIP vs EQIX
Prologis, Inc.
ANIP vs PLD
WEYERHAEUSER CO
ANIP vs WY
COSTAR GROUP, INC.
ANIP vs CSGP
$309.11M
$14.84B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
